Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Colorectal Neoplasms 476Carcinoma, Non-Small-Cell Lung 233Breast Neoplasms 196Ovarian Neoplasms 171Glioblastoma 157Carcinoma, Hepatocellular 131Neoplasms 128Rectal Neoplasms 114Colonic Neoplasms 110Neoplasm Metastasis 106Brain Neoplasms 97Lung Neoplasms 96Fallopian Tube Neoplasms 85Carcinoma, Renal Cell 77Glioma 69Pancreatic Neoplasms 54Liver Neoplasms 44Melanoma 43Gliosarcoma 43Uterine Cervical Neoplasms 40Adenocarcinoma of Lung 39Stomach Neoplasms 37Recurrence 33Astrocytoma 30Carcinoma, Ovarian Epithelial 28Endometrial Neoplasms 27Triple Negative Breast Neoplasms 26Kidney Neoplasms 23Prostatic Neoplasms 22Esophageal Neoplasms 21

Interventions

temsirolimus 1binimetinib 1Valproic Acid 1Trabectedin 1Specimen Handling 1Sirolimus 1Magnetic Resonance Imaging 1Laser Therapy 1Indocyanine Green 1Immunoglobulin G 1High-Energy Shock Waves 1Enoxaparin 1Disulfides 1Cetuximab 1Biopsy 1Bevacizumab 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Soft Tissue Neoplasms × Bevacizumab × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡